Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study  Maja Mockenhaupt, Cecile Viboud, Ariane Dunant, Luigi Naldi, Sima Halevy, Jan Nico Bouwes Bavinck, Alexis Sidoroff, Jürgen Schneck, Jean-Claude Roujeau, Antoine Flahault  Journal of Investigative Dermatology  Volume 128, Issue 1, Pages 35-44 (January 2008) DOI: 10.1038/sj.jid.5701033 Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Distribution of the number of days between beginning of drug use (drug initiation) and onset of the adverse reaction for selected drugs. (a and b) Highly associated drugs, (c and d) non-associated drugs, and (e and f) drugs with doubtful association. Dashed lines indicate cases with co-medication with another “highly suspected” drug initiated within less than 8 weeks before the onset of the reaction. Journal of Investigative Dermatology 2008 128, 35-44DOI: (10.1038/sj.jid.5701033) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions